Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
about
Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemyInvasive candidiasis: from mycobiome to infection, therapy, and prevention.Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis.Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal InfectionPharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit PatientsAbdominal Sepsis.Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model.In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.Albendazole and antibiotics synergize to deliver short-course anti-Wolbachia curative treatments in preclinical models of filariasis.Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata.Anidulafungin pharmacokinetics in ascites and pleural effusion of critically ill patients.Mutant prevention concentration and mutant selection window of micafungin and anidulafungin in clinical Candida glabrata isolates.Are we near to the end of the standard dose of micafungin?
P2860
Q26745677-443D38DC-039C-4866-B49C-B33040D329B6Q30251428-121DA045-AFE0-43ED-809B-2F6B7F7C74CBQ36708214-A86FCC9D-A269-47AA-BE05-7C5415C0CF5FQ37287812-71B2DF49-5F60-42E6-A5C6-602199F0DF86Q38681635-04013747-4A4A-4BDE-82E5-B10DAB39711DQ38683101-18807E69-B4BD-43FE-A9EC-0E2C57E9226CQ38763496-06390496-3463-4662-8892-D1DF8B6B6D62Q38882280-44ED79E8-F478-4F97-BA45-B5B40823FCAEQ39020129-B0D7A8F2-6FBD-4AAC-95FB-B5A0E3B5910CQ40100873-44AF8C30-E603-4739-A02E-8CB89542FD3DQ40121744-A1E10E9E-1C3A-4AB2-8E79-19361780F0DBQ40441738-5DC3A703-D4F0-483E-9CDE-A18AC1B0EDABQ40546653-F013C20F-B0EC-42D3-8567-E834504EF46CQ44288385-4B5FF60A-0123-4E47-9ADC-CBA739FF36F0Q47876785-0675238F-96CC-4409-BAAD-562F10EE2C46Q49936044-7B5E86F6-BFDA-4956-AF75-D24A931CF290Q50028262-95D474BA-EB8A-4B89-9690-7ABA71AC7EFEQ50134184-37BF3302-30FD-4925-A3D2-B70EC130B308Q55363448-92BB5B27-CED7-4739-8D8C-6DA2D36A537D
P2860
Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Plasma and peritoneal fluid po ...... ients with severe peritonitis.
@en
Plasma and peritoneal fluid po ...... ients with severe peritonitis.
@nl
type
label
Plasma and peritoneal fluid po ...... ients with severe peritonitis.
@en
Plasma and peritoneal fluid po ...... ients with severe peritonitis.
@nl
prefLabel
Plasma and peritoneal fluid po ...... ients with severe peritonitis.
@en
Plasma and peritoneal fluid po ...... ients with severe peritonitis.
@nl
P2093
P2860
P50
P356
P1476
Plasma and peritoneal fluid po ...... ients with severe peritonitis.
@en
P2093
C A García-Bernedo
N Campillo
U Rodríguez
P2860
P304
P356
10.1093/JAC/DKV173
P407
P577
2015-07-14T00:00:00Z